It is reasonable to assume that EGFR may be the relevant activating kinase for ErbB3 since ErbB3 has impaired kinase activity, both targets are expressed in HNSCC, and EGFR is known to be a heterodimerization partner for ErbB3 [46,47]. Here, ERBB3 is linked to head and neck squamous cell carcinoma.